JMML | opacc

FDA Approves Vidaza for Rare Pediatric Blood Cancer

The Food and Drug Administration (FDA) approved Vidaza (azacytidine) for the treatment of pediatric patients with newly diagnosed...

How a Powerful Genetic Test Matched An Infant’s Cancer to a Life-Saving Therapy

Doctors have successfully treated an infant with a rare childhood leukemia using a targeted therapy approved for adults with inoperable...

Childhood Leukemia Outcomes May Be Informed by DNA Methylation Patterns

Two studies by independent research teams have identified epigenetic subgroups in children with a rare pediatric leukemia called juvenile...

UAMS Cancer Researchers Publish Findings on Rare Childhood Leukemia

New findings on juvenile myelomonocytic leukemia (JMML) by researchers at the University of Arkansas for Medical Sciences (UAMS) and...

London scientists pioneer ‘game changing’ infrared imaging technique to treat child cancer

Heart Disease Risk Is Higher Among Childhood Cancer Survivors, Study Finds

Bone cancer drug could save children’s lives

Splicing Deregulation Detected and Targeted in Type of Childhood Leukemia

New study uncovers key culprit behind pediatric brain cancer metastasis

Safe to Skip Primary Tumor Boosts in Pediatric Germinomas

Scientists reveal how different cancer cells team up to help incurable childhood brain tumour spread

Identifying drug target candidates to treat pediatric rhabdomyosarcoma tumors

Childhood Cancer Survivors Have Higher Rate of Aging-Related Mutations Than the General Population

Children’s Cancer Institute begins trial for childhood brain cancer therapy